|
CZ298681B6
(cs)
*
|
1998-06-08 |
2007-12-19 |
F. Hoffmann-La Roche Ag |
Lécivo pro lécení infekcí chronické hepatitis C
|
|
MY164523A
(en)
*
|
2000-05-23 |
2017-12-29 |
Univ Degli Studi Cagliari |
Methods and compositions for treating hepatitis c virus
|
|
IL153020A0
(en)
|
2000-05-26 |
2003-06-24 |
Idenix Cayman Ltd |
Methods and compositions for treating flaviviruses and pestiviruses
|
|
US7208167B2
(en)
|
2000-08-07 |
2007-04-24 |
Sciclone Pharmaceuticals, Inc. |
Treatment of hepatitis C with thymosin and peptide combination therapy
|
|
EA007785B1
(ru)
*
|
2000-08-07 |
2007-02-27 |
Сайклоун Фармасьютикалз, Инк. |
Способ лечения гепатита с с помощью тимозина, интерферона и рибавирина
|
|
US7179791B2
(en)
|
2001-01-11 |
2007-02-20 |
Duke University |
Inhibiting GS-FDH to modulate NO bioactivity
|
|
JP2005504087A
(ja)
|
2001-09-28 |
2005-02-10 |
イデニクス（ケイマン）リミテツド |
４’が修飾されたヌクレオシドを使用するｃ型肝炎ウイルス治療のための方法および組成物
|
|
KR100480429B1
(ko)
*
|
2001-12-04 |
2005-04-06 |
선바이오(주) |
인터페론-알파와 폴리에틸렌글리콜 유도체의 배합체
|
|
CN1678326A
(zh)
*
|
2002-06-28 |
2005-10-05 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
US7608600B2
(en)
*
|
2002-06-28 |
2009-10-27 |
Idenix Pharmaceuticals, Inc. |
Modified 2′ and 3′-nucleoside prodrugs for treating Flaviviridae infections
|
|
EP1523489B1
(en)
|
2002-06-28 |
2014-03-12 |
IDENIX Pharmaceuticals, Inc. |
Modified 2' and 3' -nucleoside produgs for treating flaviridae infections
|
|
CN101172993A
(zh)
|
2002-06-28 |
2008-05-07 |
埃迪尼克斯(开曼)有限公司 |
用于治疗黄病毒感染的2′－c－甲基－3′－o－l－缬氨酸酯核糖呋喃基胞苷
|
|
KR20050088079A
(ko)
|
2002-11-15 |
2005-09-01 |
이데닉스 (케이만) 리미티드 |
2'-분지형 뉴클레오시드 및 플라비비리다에 돌연변이
|
|
MXPA05006230A
(es)
|
2002-12-12 |
2005-09-20 |
Idenix Cayman Ltd |
Proceso para la produccion de nucleosidos ramificados-2'.
|
|
CA2511616A1
(en)
*
|
2002-12-23 |
2004-07-15 |
Idenix (Cayman) Limited |
Process for the production of 3'-nucleoside prodrugs
|
|
ES2906207T3
(es)
|
2003-05-30 |
2022-04-13 |
Gilead Pharmasset Llc |
Análogos de nucleósidos fluorados modificados
|
|
AU2005256963A1
(en)
*
|
2004-06-23 |
2006-01-05 |
Centre National De La Recherche Scientifique |
5-aza-7-deazapurine derivatives for treating infections with flaviviridae
|
|
US7857760B2
(en)
|
2004-07-13 |
2010-12-28 |
Dexcom, Inc. |
Analyte sensor
|
|
CN101023094B
(zh)
|
2004-07-21 |
2011-05-18 |
法莫赛特股份有限公司 |
烷基取代的2-脱氧-2-氟代-d-呋喃核糖基嘧啶和嘌呤及其衍生物的制备
|
|
JP5001842B2
(ja)
|
2004-09-14 |
2012-08-15 |
ギリアド ファーマセット エルエルシー |
２’−フルオロ−２’−アルキル−置換又は他の置換されていてもよいリボフラノシルピリミジン類及びプリン類並びにそれらの誘導体の製造
|
|
WO2006056464A2
(en)
|
2004-11-26 |
2006-06-01 |
Pieris Ag |
Compound with affinity for the cytotoxic t lymphocyte-associated antigen (ctla-4)
|
|
MX2008002015A
(es)
*
|
2005-08-15 |
2008-03-25 |
Hoffmann La Roche |
Polietilenglicol-interferon alfa y ribavirina para el tratamiento del virus de hepatitis b.
|
|
US9201979B2
(en)
*
|
2005-09-14 |
2015-12-01 |
Millennial Media, Inc. |
Syndication of a behavioral profile associated with an availability condition using a monetization platform
|
|
JP5254033B2
(ja)
*
|
2005-12-23 |
2013-08-07 |
イデニク プハルマセウティカルス，インコーポレイテッド |
分岐型ヌクレオシドを調製するための合成中間体の製造方法
|
|
US7964580B2
(en)
|
2007-03-30 |
2011-06-21 |
Pharmasset, Inc. |
Nucleoside phosphoramidate prodrugs
|
|
TW200946541A
(en)
|
2008-03-27 |
2009-11-16 |
Idenix Pharmaceuticals Inc |
Solid forms of an anti-HIV phosphoindole compound
|
|
JP5711118B2
(ja)
|
2008-06-24 |
2015-04-30 |
テクニッシュ ウニヴェルジテート ミュンヘン |
所与の標的に対してアフィニティーを有するｈＮＧＡＬおよび類縁タンパク質のムテイン
|
|
JP5539363B2
(ja)
*
|
2008-09-17 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インターフェロンおよびリバビリンとのｈｃｖｎｓ３プロテアーゼ阻害剤の組合せ
|
|
EP2376515A1
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Synthesis of purine nucleosides
|
|
NZ593648A
(en)
|
2008-12-23 |
2013-09-27 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
BRPI0922508A8
(pt)
|
2008-12-23 |
2016-01-19 |
Pharmasset Inc |
Análogos de nucleosídeo
|
|
JP2012526149A
(ja)
|
2009-05-08 |
2012-10-25 |
サイクローン・ファーマシューティカルズ・インコーポレイテッド |
ワクチン増強剤としてのαチモシンペプチド
|
|
US8618076B2
(en)
|
2009-05-20 |
2013-12-31 |
Gilead Pharmasset Llc |
Nucleoside phosphoramidates
|
|
TWI598358B
(zh)
|
2009-05-20 |
2017-09-11 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
|
CA2770149A1
(en)
|
2009-08-05 |
2011-02-10 |
Pieris Ag |
Controlled release formulations of lipocalin muteins
|
|
PH12012500827A1
(en)
|
2009-10-30 |
2013-01-07 |
Boehringer Ingelheim Int |
Dosage regimens for hcv combination therapy comprising bi201335, interferon alpha and ribavirin
|
|
DK2990798T3
(da)
|
2009-12-07 |
2019-12-02 |
Pieris Pharmaceuticals Gmbh |
Muteiner af human lipocalin 2 (lcn2, hngal) med affinitet for et specifikt mål
|
|
CN102858790A
(zh)
|
2010-03-31 |
2013-01-02 |
吉利德制药有限责任公司 |
核苷氨基磷酸酯
|
|
JP5902679B2
(ja)
|
2010-06-08 |
2016-04-13 |
ピエリス アーゲーＰｉｅｒｉｓ Ａｇ |
ＩＬ−４Ｒαに結合する涙液リポカリンムテイン
|
|
KR20180088745A
(ko)
|
2010-08-16 |
2018-08-06 |
피어이스 파마슈티컬즈 게엠베하 |
헵시딘 결합 단백질
|
|
JP6100694B2
(ja)
|
2010-11-15 |
2017-03-22 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
グリピカン−３（ｇｐｃ３）に対して親和性を有するヒトリポカリン２の突然変異タンパク質
|
|
PT3042910T
(pt)
|
2010-11-30 |
2019-04-16 |
Gilead Pharmasset Llc |
2'-espiro-nucleósidos para utilização na terapia da hepatite c
|
|
DK2646552T3
(en)
|
2010-12-02 |
2017-10-23 |
Pieris Pharmaceuticals Gmbh |
MUTEINES OF HUMAN LIPOCALIN 2 WITH AFFINITY FOR CTLA-4
|
|
HRP20180237T4
(hr)
|
2011-09-16 |
2020-12-11 |
Gilead Pharmasset Llc |
Metode za liječenje hcv-a
|
|
US8889159B2
(en)
|
2011-11-29 |
2014-11-18 |
Gilead Pharmasset Llc |
Compositions and methods for treating hepatitis C virus
|
|
WO2013087660A1
(en)
|
2011-12-13 |
2013-06-20 |
Pieris Ag |
Methods for preventing or treating certain disorders by inhibiting binding of il-4 and/or il-13 to their respective receptors
|
|
WO2013174783A1
(en)
|
2012-05-23 |
2013-11-28 |
Pieris Ag |
Lipocalin muteins with binding-affinity for glypican-3 (gpc-3) and use of lipocalin muteins for target-specific delivery to cells expressing gpc-3
|
|
US20140039923A1
(en)
*
|
2012-08-03 |
2014-02-06 |
AxelaCare Health Solutions, Inc. |
Computer program, method, and system for receiving and managing patient data gathered during patient treatments
|
|
EP3441400B1
(en)
|
2012-11-19 |
2022-07-20 |
Pieris Pharmaceuticals GmbH |
Novel specific-binding polypeptides and uses thereof
|
|
KR20140119012A
(ko)
|
2013-01-31 |
2014-10-08 |
길리어드 파마셋 엘엘씨 |
두 항바이러스 화합물의 병용 제형물
|
|
JP6619650B2
(ja)
|
2013-03-14 |
2019-12-11 |
ピエリス ファーマシューティカルズ ゲーエムベーハー |
新規のｐｃｓｋ９結合タンパク質
|
|
US20150064253A1
(en)
|
2013-08-27 |
2015-03-05 |
Gilead Pharmasset Llc |
Combination formulation of two antiviral compounds
|
|
CA2936611A1
(en)
|
2014-01-13 |
2015-07-16 |
Pieris Pharmaceuticals Gmbh |
Multi-specific polypeptide useful for localized tumor immunomodulation
|
|
CA2949405C
(en)
|
2014-05-22 |
2023-08-01 |
Pieris Pharmaceuticals Gmbh |
Novel specific-binding polypeptides and uses thereof
|
|
EP3250586B1
(en)
|
2015-01-28 |
2021-10-27 |
Pieris Pharmaceuticals GmbH |
Novel proteins specific for angiogenesis
|
|
TW201636364A
(zh)
|
2015-02-18 |
2016-10-16 |
賽諾菲公司 |
對於螢光鐵載體及綠膿桿菌螯鐵蛋白具特異性之新穎蛋白
|
|
MX2017014082A
(es)
|
2015-05-04 |
2018-06-28 |
Pieris Pharmaceuticals Gmbh |
Nuevas proteinas especificas para cd137.
|
|
RU2727165C2
(ru)
|
2015-05-04 |
2020-07-21 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Слитый полипептид с противораковой активностью
|
|
RU2021119777A
(ru)
|
2015-05-18 |
2021-08-16 |
ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ |
Слитый полипептид, способный связывать cd137 и gpc3, молекула нуклеиновой кислоты, содержащая нуклеотидную последовательность, кодирующую такой слитый полипептид, способ его получения и пути применения
|
|
US10273275B2
(en)
|
2015-05-18 |
2019-04-30 |
Pieris Pharmaceuticals Gmbh |
Muteins of human lipocalin 2 with affinity for glypican-3 (GPC3) and methods of use thereof
|
|
EP3115371A1
(en)
|
2015-07-07 |
2017-01-11 |
Sanofi |
Fusion molecules
|
|
CN108348573A
(zh)
|
2015-07-15 |
2018-07-31 |
皮里斯制药有限公司 |
Lag-3特异性的新型蛋白
|
|
AU2016363668A1
(en)
|
2015-11-30 |
2018-05-24 |
Pieris Australia Pty Ltd. |
Novel anti-angiogenic fusion polypeptides
|
|
TW201725212A
(zh)
|
2015-12-10 |
2017-07-16 |
第一三共股份有限公司 |
特異性於降鈣素基因相關胜肽的新穎蛋白
|
|
WO2018087108A1
(en)
|
2016-11-09 |
2018-05-17 |
Pieris Pharmaceuticals Gmbh |
Proteins specific for cd137
|
|
EP3571219A1
(en)
|
2017-01-18 |
2019-11-27 |
Pieris Pharmaceuticals GmbH |
Lipocalin muteins with binding affinity for lag-3
|
|
ES2948717T3
(es)
|
2018-07-31 |
2023-09-18 |
Pieris Pharmaceuticals Gmbh |
Nueva proteína de fusión específica para CD137 y PD-L1
|
|
BR112021016829A2
(pt)
|
2019-02-26 |
2021-10-19 |
Pieris Pharmaceuticals Gmbh |
Proteínas de fusão, molécula de ácido nucleico, métodos de produção, de ativar simultaneamente as vias de sinalização, de coestimular células t, de induzir uma resposta de linfócitos e de induzir o aumento da citólise, composição farmacêutica e método para prevenir, melhorar ou tratar cânceres
|
|
CA3177098A1
(en)
|
2020-06-05 |
2021-12-09 |
Pieris Pharmaceuticals Gmbh |
Multimeric immunomodulator targeting 4-1bb
|
|
KR20230165917A
(ko)
|
2021-04-08 |
2023-12-05 |
피어이스 파마슈티컬즈 게엠베하 |
결합 조직 성장 인자(ctgf)에 특이적인 신규 리포칼린 뮤테인
|
|
WO2022243341A1
(en)
|
2021-05-18 |
2022-11-24 |
Pieris Pharmaceuticals Gmbh |
Lipocalin muteins with binding affinity for ox40
|
|
TW202428603A
(zh)
|
2022-09-21 |
2024-07-16 |
美商思進公司 |
新穎的cd137及cd228特異性融合蛋白
|
|
WO2025175123A1
(en)
|
2024-02-16 |
2025-08-21 |
Seagen Inc. |
Methods of treating cancer using fusion proteins specific for cd137 and cd228
|